TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

ORAVIG

MICONAZOLE
Infectious Disease Approved 2010-04-16
1
Indication
--
Phase 3 Trials
15
Years on Market

Details

Status
Prescription
First Approved
2010-04-16
Routes
BUCCAL
Dosage Forms
TABLET

Companies

Active Ingredient: MICONAZOLE

ORAVIG Approval History

Loading approval history...

What ORAVIG Treats

1 indications

ORAVIG is approved for 1 conditions since its original approval in 2010. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Oropharyngeal Candidiasis
Source: FDA Label
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

ORAVIG FDA Label Details

Pro

Indications & Usage

FDA Label (PDF)

1 INDICATIONS & USAGE ORAVIG is indicated for the local treatment of oropharyngeal candidiasis (OPC) in adults. ORAVIG is an azole antifungal indicated for the local treatment of oropharyngeal candidiasis in adults.

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.